Delving into the Latest Updates on Takeda Pharma GmbH with Synapse

概览

关联

3

项与 Takeda Pharma GmbH 相关的临床试验

EUCTR2006-002354-30-DE / Not yet recruitingN/A

Effect of Acute Insulin Intervention followed by Pioglitazone and Metformin Treatment on Metabolic Parameters in Type 2 Diabetic Patients with inadequate Metabolic Control

开始日期2006-07-27

申办/合作机构

Takeda Pharma GmbH

EUCTR2004-004226-28-DE / Not yet recruitingN/A

Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications

开始日期2005-01-17

申办/合作机构

Takeda Pharma GmbH

EUCTR2004-003962-14-DE / Not yet recruitingN/A

Candesartan added Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters.An open, non-controlled and multicentre trial

开始日期2004-12-16

申办/合作机构

Takeda Pharma GmbH

100 项与 Takeda Pharma GmbH 相关的临床结果

登录后查看更多信息

0 项与 Takeda Pharma GmbH 相关的专利（医药）

登录后查看更多信息

9

项与 Takeda Pharma GmbH 相关的文献（医药）

2011-09-01·Drug Safety2区 · 医学

Can Social Media Benefit Drug Safety?

2区 · 医学

Article

作者: Franzen, Willibert

2011-07-01·Journal of Diabetes Science and Technology

Effect of Pioglitazone and Ramipril on Biomarkers of Low-Grade Inflammation and Vascular Function in Nondiabetic Patients with Increased Cardiovascular Risk and an Activated Inflammation: Results from the PIOace Study

Article

作者: Dekordi, Lida A. ; Hanefeld, Markolf ; Forst, Thomas ; Müller, Jürgen ; Fuchs, Winfried ; Pfützner, Andreas ; Kleine, Iris

Aims: This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk. Methods and Results: Patients enrolled in this placebo-controlled, double-blind, randomized, parallel trial (72 male, 77 female, aged 60 ± 9 years, body mass index 30.4 ± 4.7 kg/m2, duration of hypertension 9 ± 8 years) were treated with either 30/45 mg PIO (dose titration), 2.5/5 mg RAM, or their combination for 12 weeks. A reduction in high-sensitivity C-reactive protein was observed with PIO (−0.89 ± 1.98 mg/liter; −25%) and PIRA (−0.49 ± 2.11 mg/liter; −16%), while an increase was seen with RAM (0.58 ± 2.13 mg/liter; +20%, p < .05 vs PIO and PIRA). The 24-hour blood pressure profile showed a small increase with both monotherapies but a decrease with PIRA ( p < .05 vs PIO). Improvements in biomarkers of chronic systemic inflammation and insulin resistance (IR) were observed in the PIO and PIRA arms only [PIO/RAM/PIRA: homeostasis model of assessment of IR: −0.78 ± 1.39 (−29%)/0.15 ± 1.03 (+5%)/ −1.44 ± 2.83 (−40%); adiponectin: 8.51 ± 5.91 (+104%)/ 0.09 ± 2.63 (+1%)/ 8.86 ± 6.37 mg/liter (+107%); matrix metalloproteinase-9: −48 ± 127 (−12%)/−1 ± 224 (0%)/−60 ± 210 ng/ml (−13%), p < .05 for RAM vs PIO or PIRA in all cases]. Conclusions: Our 3-month study in nondiabetic hypertensive patients showed a decrease in biomarkers of IR and chronic systemic inflammation with the PIO monotherapy and the PIRA combination only, which may help to explain some findings in other cardiovascular outcome trials.

2010-10-01·Clinical Science2区 · 医学

Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus

2区 · 医学

Article

作者: Lehmann, Ute ; Hohberg, Cloth ; Weber, Matthias M. ; Müller, Jürgen ; Löbig, Mirjam ; Fuchs, Winfried ; Forst, Thomas ; Pfützner, Andreas ; Friedrich, Christiane

The aim of the present study was to compare the effect of PIO (pioglitazone) or GLIM (glimepiride) on erythrocyte deformability in T2DM (Type 2 diabetes mellitus). The study covered 23 metformin-treated T2DM patients with an HbA1c (glycated haemoglobin) >6.5%. Patients were randomized to receive either PIO (15 mg, twice a day) or GLIM (1 mg, twice a day) in combination with metformin (850 mg, twice a day) for 6 months. Blood samples were taken for the measurement of fasting glucose, HbA1c, fasting insulin, intact proinsulin, adiponectin and Hct (haematocrit). In addition, the erythrocyte EI (elongation index) was measured using laser diffractoscopy. Both treatments significantly improved HbA1c levels (PIO, −0.9±1.1%; GLIM, −0.6±0.4%; both P<0.05) and resulted in comparable HbA1c levels after 6 months (PIO, 6.5±1.2%; GLIM, 6.2±0.4%) Treatment with PIO reduced fasting insulin levels (−8.7±15.8 milli-units/l; P=0.098), intact proinsulin levels (−11.8±9.5 pmol/l; P<0.05) and Hct (−1.3±2.3%; P=0.09), whereas adiponectin levels increased (8.2±4.9 μg/ml; P<0.05). No significant change in these parameters was observed during GLIM treatment. PIO improved the EI, resulting in a significant increase in EI at all physiological shear stress ranges (0.6–6.0 Pa; P<0.05). The improvement in EI correlated with the increase in adiponectin levels (r=0.74; P<0.001), and inversely with intact proinsulin levels (r=−0.47; P<0.05). This is the first study showing an improvement in EI during treatment with PIO, which was associated with an increase in adiponectin and a decrease in intact proinsulin levels, but independent of glycaemic control.

100 项与 Takeda Pharma GmbH 相关的药物交易

登录后查看更多信息

100 项与 Takeda Pharma GmbH 相关的转化医学

登录后查看更多信息